Results 51 to 60 of about 8,086 (190)

Morphological features of TMPRSS2–ERG gene fusion prostate cancer [PDF]

The Journal of Pathology, 2007
AbstractThe TMPRSS2–ETS fusion prostate cancers comprise 50–70% of the prostate‐specific antigen (PSA)‐screened hospital‐based prostate cancers examined to date, making it perhaps the most common genetic rearrangement in human cancer. The most common variant involves androgen‐regulated TMPRSS2 and ERG, both located on chromosome 21.
J. Mosquera, S. Perner, Demichelis, Francesca, R. Kim, M. D. Hofer, K. D. Mertz, P. L. Paris, J. Simko, C. Collins, T. A. Bismar, A. M. Chinnaiyan, M. A. Rubin   +11 more
openaire   +3 more sources

Status of TMPRSS2–ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism

Prostate International, 2018
Background: Prostate cancer (PCa) shows considerable clinical heterogeneity that has been primarily attributed to variable molecular alterations. TMPRSS2–ERG fusion is one such molecular subtype that has been associated with predominantly poor prognosis.
Aparna Bhanushali, Pranesh Rao, Vaishnavi Raman, Prajakta Kokate, Asawari Ambekar, Swarna Mandva, Simi Bhatia, B.R. Das   +7 more
doaj   +1 more source

Detection of TMPRSS2-ERG fusion gene in benign prostatic hyperplasia

Tumor Biology, 2014
The Ets-related gene fusions are among the most common molecular alterations in prostate cancer (PCa) and are detected in more than 50 % of PCas. Transmembrane protease serine 2 and Ets-related gene fusion (TMPRSS2-ERG) is the most frequently identified chimeric gene and has been associated with undifferentiated and invasive phenotypes. TMPRSS2-ERG has
S, Velaeti, E, Dimitriadis, K, Kontogianni-Katsarou, A, Savvani, E, Sdrolia, G, Pantazi, S, Stefanakis, T, Trangas, N, Pandis, K, Petraki   +9 more
openaire   +2 more sources

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer [PDF]

Anticancer Research, 2016
Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate ...
Vlastimil, Kulda, Ondrej, Topolcan, Radek, Kucera, Michaela, Kripnerova, Kristyna, Srbecka, Milan, Hora, Ondrej, Hes, Jiri, Klecka, Vaclav, Babuska, Milena, Rousarova, Veronika, Benson, Martin, Pesta   +11 more
openaire   +2 more sources

Analysis of Fascin-1 in Relation to Gleason Risk Classification and Nuclear ETS-Related Gene Status of Human Prostate Carcinomas:An Immunohistochemical Study of Clinically Annotated Tumours From the Wales Cancer Bank [PDF]

, 2017
Although prostate-specific antigen (PSA) testing can identify early-stage prostate cancers, additional biomarkers are needed for risk stratification. In one study, high levels of the actin-bundling protein, fascin-1, were correlated with lethal-phase ...
Adams, Jo, Clarke, Alan R, Jefferies, Matthew T, Kynaston, Howard G, Martin, Richard, Pope, Christopher S   +5 more
core   +4 more sources

TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions

Neoplasia: An International Journal for Oncology Research, 2006
TMPRSS2-ETS gene fusions have been found recurrently in prostate carcinomas, but not in the presumed precursor lesion, high-grade prostatic intraepithelial neoplasia (HGPIN). However, HGPIN lesions may share chromosomal changes with prostate cancer.
Nuno Cerveira, Franclim R. Ribeiro, Ana Peixoto, Vera Costa, Rui Henrique, Carmen Jerönimo, Manuel R. Teixeira   +6 more
doaj   +1 more source

Significance of the TMPRSS2:ERG gene fusion in prostate cancer. [PDF]

Mol Med Rep, 2017
The transmembrane protease serine 2:v‑ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion is common in prostate cancer, while its functional role is not fully understood. The present study aimed to investigate the significance of the TMPRSS2:ERG gene fusion in human prostate cancers using bioinformatics tools.
Wang Z, Wang Y, Zhang J, Hu Q, Zhi F, Zhang S, Mao D, Zhang Y, Liang H, Liang H.   +9 more
europepmc   +4 more sources

Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis

Cancer Cell International, 2018
Background Prostate cancer is a major malignancy in males. TMPRSS2-ERG is a high-frequency fusion gene expressed in prostate cancer and plays a vital role in carcinogenesis.
Chunjiao Song, Huan Chen
doaj   +1 more source

Fusion sequencing via terminator‐assisted synthesis (FTAS‐seq) identifies TMPRSS2 fusion partners in prostate cancer

Molecular Oncology, 2023
Genetic rearrangements that fuse an androgen‐regulated promoter area with a protein‐coding portion of an originally androgen‐unaffected gene are frequent in prostate cancer, with the fusion between transmembrane serine protease 2 (TMPRSS2) and ETS ...
Ugnė Drazdauskienė, Žana Kapustina, Justina Medžiūnė, Varvara Dubovskaja, Rasa Sabaliauskaitė, Sonata Jarmalaitė, Arvydas Lubys   +6 more
doaj   +1 more source

Frequent down-regulation of ABC transporter genes in prostate cancer [PDF]

, 2015
Background: ATP-binding cassette (ABC) transporters are transmembrane proteins responsible for the efflux of a wide variety of substrates, including steroid metabolites, through the cellular membranes.
Deividas Razanauskas, Feliksas Jankevicius, Juozas Rimantas Lazutka, Kristina Daniunaite, Rita Demidenko, Sonata Jarmalaite   +5 more
core   +1 more source